Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 10, 2013, Pages 893-903

  Caberlotto, Laura ^a,b   Carboni, Lucia ^a   Zanderigo, Floriana ^a,c   Andreetta, Filippo ^a,c   Andreoli, Michela ^a,c   Gentile, Gabriella ^a,c   Razzoli, Maria ^a,d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF TRENTO   (Italy)

^c Aptuit Inc   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Amphetamine induced hyperlocomotion; Blood BDNF levels; Blood hormone levels; CRMP2; GSK3 inhibitors; Lithium

Indexed keywords

1H THIENO[2,3 C]PYRAZOL 3 YL DERIVATIVE; AMPHETAMINE; AZ 1080; BRAIN DERIVED NEUROTROPHIC FACTOR; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; FOLLITROPIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; LITHIUM; LUTEINIZING HORMONE; MELATONIN; THYROTROPIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN NERVE CELL; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HORMONE BLOOD LEVEL; IC 50; LOCOMOTION; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; TREATMENT RESPONSE;

ANIMALS; BRAIN; CELLS, CULTURED; GASTRIC EMPTYING; GLYCOGEN SYNTHASE KINASE 3; HORMONES; LITHIUM COMPOUNDS; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NEURONS; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84884672711     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0893-9     Document Type: Article

References (68)

1. Ahnaou A, Drinkenburg WH (2011) Disruption of glycogen synthase kinase-3-beta activity leads to abnormalities in physiological measures in mice. Behav Brain Res 221:246-52
2. Anderson LL, Scanes CG (2012) Nanobiology and physiology of growth hormone secretion. Exp Biol Med 237:126-42
3. Angelucci F, Aloe L, Jiménez-Vasquez P, Mathé AA (2003) Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. Int J Neuropsychopharmacol 6:225-31
4. Banerji TK, Parkening TA, Collins TJ, Rassoli A (1983) Lithium-induced changes in the plasma and pituitary levels of luteinizing hormone, follicle stimulating hormone and prolactin in rats. Life Sci 33:1621-7
5. Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR, Caron MG (2004) Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 101:5099-50104
6. Berg S, Hellberg S, Nylöf M, Xue Y (2003) WO2003082853 A1
7. Bou Khalil R, Richa S (2011) Thyroid adverse effects of psychotropic drugs: a review. Clin Neuropharmacol 34:248-55
8. Catapano LA, Manji HK (2008) Kinases as drug targets in the treatment of bipolar disorder. Drug Discov Today 13:295-302
9. Chalecka-Franaszek E, Chuang DM (1999) Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 96:8745-50
10. Chen G, Huang LD, Jiang YM, Manji HK (1999) The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72:1327-30
11. Cole AR, Knebel A, Morrice NA, Robertson LA, Irving AJ, Connolly CN, Sutherland C (2004) GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J Biol Chem 279:50176-80
12. Cole AR, Causeret F, Yadirgi G, Hastie CJ, McLauchlan H, McManus EJ, Hernández F, Eickholt BJ, Nikolic M, Sutherland C (2006) Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. J Biol Chem 281:16591-8
13. Cole AR, Noble W, van Aalten L, Plattner F, Meimaridou R, Hogan D, Taylor M, LaFrancois J, Gunn-Moore F, Verkhratsky A, Oddo S, LaFerla F, Giese KP, Dineley KT, Duff K, Richardson JC, Yan SD, Hanger DP, Allan SM, Sutherland C (2007) Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J Neurochem 103:1132-44
14. Cox C, Harrison-Read PE, Steinberg H, Tomkiewicz M (1971) Lithium attenuates drug-induced hyperactivity in rats. Nature 232:336-8
15. Coyle-Rink J, Del Valle L, Sweet T, Khalili K, Amini S (2002) Developmental expression of Wnt signaling factors in mouse brain. Cancer Biol Ther 1:640-5
16. Culbert AA, Brown MJ, Frame S, Hagen T, Cross DA, Bax B, Reith AD (2001) GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and beta-catenin stabilisation without elevation of glycogen synthase activity. FEBS Lett 507:288-94
17. De Sarno P, Li X, Jope RS (2002) Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43:1158-64
18. de Sousa RT, van de Bilt MT, Diniz BS, Ladeira RB, Portela LV, Souza DO, Forlenza OV, Gattaz WF, Machado-Vieira R (2011) Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett 494:54-6
19. Di Daniel E, Mudge AW, Maycox PR (2005) Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons. Bipolar Disord 7:33-741
20. Diniz BS, Teixeira AL (2011) Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond. Neuromolecular Med 13:217-22
21. Duman RS, Voleti B (2012) Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 35:47-56
22. Embi N, Rylatt DB, Cohen P (1980) Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107:519-27
23. Enman NM, Unterwald EM (2012) Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse. Behav Brain Res 231:217-25
24. Fernandes BS, Gama CS, Ceresér KM, Yatham LN, Fries GR, Colpo G, de Lucena D, Kunz M, Gomes FA, Kapczinski F (2011) Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 45:995-1004
25. Frey BN, Andreazza AC, Ceresér KM, Martins MR, Valvassori SS, Réus GZ, Quevedo J, Kapczinski F (2006) Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci 79:281-6
26. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S (2001) Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology 158:100-6
27. Gardner S, Maudsley S, Millar RP, Pawson AJ (2007) Nuclear stabilization of beta-catenin and inactivation of glycogen synthase kinase-3beta by gonadotropin-releasing hormone: targeting Wnt signaling in the pituitary gonadotrope. Mol Endocrinol 21:3028-38
28. Gould TD, Chen G, Manji HK (2004) In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 29:32-8
29. Gould D, Einat H, O'Donnell KC, Picchini AM, Schloesser RJ, Manji HK (2007) Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology 32:2173-83
30. Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65:391-426
31. Hammonds MD, Shim SS (2009) Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Basic Clin Pharmacol Toxicol 105:113-9
32. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM (2002) Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43:1173-9
33. Jacobsen JP, Mørk A (2004) The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res 1024:183-92
34. Jope RS (2003) Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24:441-3
35. Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29:95-102
36. Kalinichev M, Dawson LA (2011) Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. Int J Neuropsychopharmacol 14:1051-67
37. Khattak MN, Buchfelder M, Kleindienst A, Schöfl C, Kremenevskaja N (2010) CRH and SRIF have opposite effects on the Wnt/β-catenin signalling pathway through PKA/GSK-3β in corticotroph pituitary cells. Cancer Invest 28:797-805
38. Klein PS, Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93:8455-9
39. Kozikowski AP, Gunosewoyo H, Guo S, Gaisina IN, Walter RL, Ketcherside A, McClung CA, Mesecar AD, Caldarone B (2011) Identification of a glycogen synthase kinase-3β inhibitor that attenuates hyperactivity in CLOCK mutant mice. ChemMedChem 6:1593-602
40. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM (2008) Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 28:2576-88
41. Lerer B, Globus M, Brik E, Hamburger R, Belmaker RH (1984) Effect of treatment and withdrawal from chronic lithium in rats on stimulant-induced responses. Neuropsychobiology 11:28-32
42. Leyhe T, Eschweiler GW, Stransky E, Gasser T, Annas P, Basun H, Laske C (2009) Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis 16:649-56
43. Lim YW, Yoon SY, Choi JE, Kim SM, Lee HS, Choe H, Lee SC, Kim DH (2010) Maintained activity of glycogen synthase kinase-3beta despite of its phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model. Biochem Biophys Res Commun 395:207-12
44. Martinez A, Perez DI (2008) GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J Alzheimers Dis 15:181-91
45. McCann MJ, Verbalis JG, Stricker EM (1989) LiCl and CCK inhibit gastric emptying and feeding and stimulate OT secretion in rats. Am J Physiol 256:R463-8
46. Miller JS, Tallarida RJ, Unterwald EM (2009) Cocaine-induced hyperactivity and sensitization are dependent on GSK3. Neuropharmacology 56:1116-23
47. Nishino S, Ohtomo K, Numata Y, Sato T, Nakahata N, Kurita M (2012) Divergent effects of lithium and sodium valproate on brain-derived neurotrophic factor (BDNF) production in human astrocytoma cells at therapeutic concentrations. Prog Neuropsychopharmacol Biol Psychiatry 39:17-22
48. O'Brien WT, Klein PS (2009) Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans 37:1133-8
49. Omata N, Murata T, Takamatsu S, Maruoka N, Mitsuya H, Yonekura Y, Fujibayashi Y, Wada Y (2008) Neuroprotective effect of chronic lithium treatment against hypoxia in specific brain regions with upregulation of cAMP response element binding protein and brain-derived neurotrophic factor but not nerve growth factor: comparison with acute lithium treatment. Bipolar Disord 10:360-8
50. Pérez M, Hernández F, Lim F, Díaz-Nido J, Avila J (2003) Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 5:301-8
51. Phiel CJ, Klein PS (2001) Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41:789-813
52. Quiroz JA, Gould TD, Manji HK (2004) Molecular effects of lithium. Mol Interv 4:259-72
53. Quiroz JA, Machado-Vieira R, Zarate CA Jr, Manji HK (2010) Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 62:50-60
54. Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A (2009) Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 156:885-98
55. Rotte A, Pasham V, Eichenmüller M, Yang W, Qadri SM, Bhandaru M, Lang F (2010) Regulation of basal gastric acid secretion by the glycogen synthase kinase GSK3. J Gastroenterol 45:1022-32
56. Ryves WJ, Dajani R, Pearl L, Harwood AJ (2002) Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem Biophys Res Commun 290:967-72
57. Seggie J, Werstiuk ES, Joshi M (1985) Lithium and twenty-four hour rhythms of serum corticosterone, prolactin and growth hormone in pigmented eye rats. Prog Neuropsychopharmacol Biol Psychiatry 9:755-8
58. Smythe GA, Brandstater JF, Lazarus L (1979) Acute effects of lithium on central dopamine and serotonin activity reflected by inhibition of prolactin and growth hormone secretion in the rat. Aust J Biol Sci 32:329-34
59. Su Y, Ryder J, Li B, Wu X, Fox N, Solenberg P, Brune K, Paul S, Zhou Y, Liu F, Ni B (2004) Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 43:6899-908
60. Suwalska A, Sobieska M, Rybakowski JK (2010) Serum brain-derived neurotrophic factor in euthymic bipolar patients on prophylactic lithium therapy. Neuropsychobiology 62:229-34
61. Tonani R, Bindi S, Fancelli D, Pittalà V, D' Anello M (2004) WO2004007504 A1
62. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ (1998) Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37:1553-1561
63. Xu CM, Wang J, Wu P, Xue YX, Zhu WL, Li QQ, Zhai HF, Shi J, Lu L (2011) Glycogen synthase kinase 3β in the nucleus accumbens core is critical for methamphetamine-induced behavioral sensitization. J Neurochem 118:126-39
64. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM (2009) The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14:51-9
65. Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K (2005) GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120:137-49
66. Yoshimura R, Tsuji K, Ueda N, Nakamura J (2007) Increase of plasma brain-derived neurotrophic factor levels in two psychotic depressed patients responding to lithium addition to paroxetine treatment. Neuropsychiatr Dis Treat 3:683-6
67. Yu X, Malenka RC (2004) Multiple functions for the cadherin/catenin complex during neuronal development. Neuropharmacology 47:779-86
68. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS (2003) Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem 278:33067-77